Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with ...
Researchers assess whether GLP-1 receptor agonists increase the risk of suicide, self-harm, or suicidal ideation in type 2 ...
Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class ...
Taiwan: A recent cohort study has highlighted the potential benefits of combining glucagon-like peptide-1 receptor agonists ...
Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have ...
Opens in a new tab or window Older adults with type 2 diabetes newly treated with a GLP-1 receptor agonist had a lower risk for depression than DPP-4 inhibitor users. There was no difference for ...
Consumers taking GLP-1 drugs like Ozempic will need to adapt their shopping habits and diets, opening opportunities for food ...
For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with ...
Obesity and diabetes have been two of the greatest public health challenges for decades. Many different diets and fads have promised the public ...
Risk of suicidality wasn't higher for type 2 diabetes patients starting on GLP-1 receptor agonists than for those on two ...
Evidence suggests no increased risk The use of glucagon-like peptide-1 (GLP-1) receptor agonists has surged in recent years, driven by their benefits in glucose control in type 2 diabetes, weight ...
Treatment for OUD is currently dominated by opioid agonist therapies that are highly regulated due to their liability for ...